bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S6 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S6 - PDF file 97K, Indirect non-invasive imaging of yCD suicide gene expression through 2A-mediated bicistronic co-expression of luciferase reporter gene and yCD suicide gene. Corresponding quantifications of total flux emitted from tumors injected with AH-6CC-L2C were shown in A, for Fig. 3 (subcutaneous model) and B, for Fig. 4 (orthotopic model). Red arrows indicated the time point when AH-6CC-L2C (3 � 106 TU per dose) was injection. Blue double head arrow indicated the period during which 2 daily doses of corresponding 5-FC or PBS were i.p. administered at 6 h interval. The total flux was calculated by drawing a ROI with the Living Image software. All data were presented as mean plus-minus SEM, n = 5
Supplementary Figure 2 from Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response
Authors: Cesca Marta , Morosi Lavinia , Berndt Alexander , Nerini Ilaria Fuso , Frapolli Roberta , Richter Petra , Decio Alessandra , Dirsch Olaf , Micotti Edoardo , Giordano Silvia , D'Incalci Maurizio , Davoli Enrico , Zucchetti Massimo , Giavazzi Raffaella
Published: April 2023

MALDI MSI analysis of PTX, and PTX tumor uptake in orthotopic A2780-1A9 tumors from mice pretreated with bevacizumab
Supplementary Figure 1 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDF - 274K, Inducible CENP-E shRNA analysis.
Supplementary Figures 1-4 and Supplementary Tables 1-3 from Combination Therapy for KIT-Mutant Mast Cells: Targeting Constitutive NFAT and KIT Activity
Authors: Macleod Alison C. , Klug Lillian R. , Patterson Janice , Griffith Diana J. , Beadling Carol , Town Ajia , Heinrich Michael C.
Published: April 2023

Figure S1: HMC1.2 cell line has constitutively actived NFAT2, NFAT2 and NFAT4 species; Figure S2: RT-PCR of transcripts modulated by 24 hour treatment with CSA; Figure S3: CNPIs do not modulate KIT signaling and KIT inhibitors do not affect NFAT localization; Figure S4: Combination therapy does not enhance the effect of KIT inhibitors on KIT or downstream signaling; Table S1: Summary of KIT-mutant mast cell characteristics; Table S2: Summary of antibodies used in immunoblotting experiments; Table S3: qRT-PCR analysis of NFAT expression in KIT-mutant mast cell lines.
Supplementary Figure 3 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 194K, MT189 causes cellular microtubulin depolymerization in a time-dependent manner and induces reversible M arrest.
Supplemental Figure 1 from Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status
Authors: Cummings Christopher T. , Zhang Weihe , Davies Kurtis D. , Kirkpatrick Gregory D. , Zhang Dehui , DeRyckere Deborah , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Graham Douglas K.
Published: April 2023

Supplemental Figure 1: Lack of Expression of Relevant Potential Off-Target Kinases.Sub-confluent cultures of the H2228, A549, Colo699, and H1299 NSCLC cell lines were lysed.
Supplementary Figure 1 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Figure 1: High-resolution heatmap of complete EC50 dataset after hierarchical clustering.
Supplemental Table 3 from Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors
Authors: Dayekh Khalil , Johnson-Obaseki Stephanie , Corsten Martin , Villeneuve Patrick J. , Sekhon Harmanjatinder S. , Weberpals Johanne I. , Dimitroulakos Jim
Published: April 2023

Table of the patient characteristics of the ex-vivo tissue samples evaluated in this study.
Supplementary figure 3 from Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Authors: van der Watt Pauline J. , Chi Alicia , Stelma Tamara , Stowell Catherine , Strydom Erin , Carden Sarah , Angus Liselotte , Hadley Kate , Lang Dirk , Wei Wei , Birrer Michael J. , Trent John O. , Leaner Virna D.
Published: April 2023

Body mass graphs from in vivo studies showing no change in body weight over the treatment time-courses.
Supplementary Table 2 from Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Authors: van der Watt Pauline J. , Chi Alicia , Stelma Tamara , Stowell Catherine , Strydom Erin , Carden Sarah , Angus Liselotte , Hadley Kate , Lang Dirk , Wei Wei , Birrer Michael J. , Trent John O. , Leaner Virna D.
Published: April 2023

IC50 values obtained from INI-43 treatment of cancer, transformed and normal cell lines.
Supplementary Table 2 from Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Authors: Lenhart Ryan , Kirov Stefan , Desilva Heshani , Cao Jian , Lei Ming , Johnston Kathy , Peterson Russell , Schweizer Liang , Purandare Ashok , Ross-Macdonald Petra , Fairchild Craig , Wong Tai , Wee Susan
Published: April 2023

Microarray data for the 5 probe sets that show differential responses to JQ1 treatment. Shown are the Affymetrix RMA anti-log values of probe intensity with each treatment, together with the fold change in signal from JQ1 treatment and the JQ1 concentrations needed to achieve 50% increase or decrease in signal (EC50).
Supplementary Table 1 from Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
Authors: Lenhart Ryan , Kirov Stefan , Desilva Heshani , Cao Jian , Lei Ming , Johnston Kathy , Peterson Russell , Schweizer Liang , Purandare Ashok , Ross-Macdonald Petra , Fairchild Craig , Wong Tai , Wee Susan
Published: April 2023

JQ1 sensitivity and oncogene mutation or DNA copy number status of small cell lung cancer cell lines. Genomic information was obtained from the COSMIC database (23).
Supplemental Figure 3 from MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Authors: Xiao Yu , Nimmer Paul , Sheppard George S. , Bruncko Milan , Hessler Paul , Lu Xin , Roberts-Rapp Lisa , Pappano William N. , Elmore Steven W. , Souers Andrew J. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplemental Figure 3: MCL-1 dependency dictates cellular response to the CDK9 inhibitor flavopiridol and correlates with kinetics of death resulting from MCL-1 siRNA treatment.
Supplementary data from Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Authors: Calpe Silvia , Wagner Koen , El Khattabi Mohamed , Rutten Lucy , Zimberlin Cheryl , Dolk Edward , Verrips C. Theo , Medema Jan Paul , Spits Hergen , Krishnadath Kausilia K.
Published: April 2023

Supplementary file containing Supplementary materials and methods, supplementary figure legends and supplementary references.
Figure S1 from Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling Pathway
Authors: Liu Qiao , Xu Xiuhua , Zhao Minnan , Wei Zhao , Li Xi , Zhang Xiyu , Liu Zhaojian , Gong Yaoqin , Shao Changshun
Published: April 2023

Figure S1. DNA damage response is not required for berberine-induced senescence
Supplementary Figure 1-6 from HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells
Authors: Li Chien-Feng , Tsai Hsin-Hwa , Ko Chiung-Yuan , Pan Yen-Chun , Yen Chia-Jui , Lai Hong-Yue , Yuh Chiou-Hwa , Wu Wan-Chen , Wang Ju-Ming
Published: April 2023

Supplemental Figure 1. Anti-cancer drugs induce CEBPD expression in liver cancer cells. Supplemental Figure 2. Scheme of depression of epigenetic effects to enhance HMDB-induced CEBPD expression and apoptosis. Supplemental Figure 3. (Related to Figure 5) The p38/CREB pathway mediates HMDB-induced CEBPD transcriptional activation and CEBPD participates in HMDB-induced apoptosis in liver cancer cells. Supplemental Figure 4. (Related to Figure 5) Combinatorial treatment of HMDB and 5-AzadC can additively affect cell death. Supplemental Figure 5. (Related to Figure 5) Enhanced cytotoxic effects of HMDB combined with 5-AzadC on Huh7 and HepG2 cells. Supplemental Figure 6. (Related to Figure 5) Loss of CEBPD attenuated dual treatment-induced tumor killing in liver cancer cells.
Supplementary Figure Legend from Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
Authors: Kim Seung Tae , Jang Hye-Lim , Lee Su Jin , Lee Jeeyun , Choi Yoon-La , Kim Kyoung-Mee , Cho Jeonghee , Park Se Hoon , Park Young Suk , Lim Ho Yeong , Yashiro Masakazu , Kang Won Ki , Park Joon Oh
Published: April 2023

Legend for Supplementary Figure 1
Supplementary Figure 4 from Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Authors: Molloy Mary Ellen , White Bethany E. Perez , Gherezghiher Teshome , Michalsen Bradley T. , Xiong Rui , Patel Hitisha , Zhao Huiping , Maximov Philipp Y. , Jordan V. Craig , Thatcher Gregory R.J. , Tonetti Debra A.
Published: April 2023

Supplementary Figure 4: The calibration standards were prepared by spiking working solution and IS (20ng/mL) into blank mouse plasma, giving final BTC concentrations of 5,10, 20, 30, 40, 50, and 100 ng/mL.
Supplementary Figure 1 from Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Authors: Molloy Mary Ellen , White Bethany E. Perez , Gherezghiher Teshome , Michalsen Bradley T. , Xiong Rui , Patel Hitisha , Zhao Huiping , Maximov Philipp Y. , Jordan V. Craig , Thatcher Gregory R.J. , Tonetti Debra A.
Published: April 2023

Supplementary Figure 1: Western blot showing ERalpha expression in T47D:A18/neo, T47D:A18/PKCalpha, T47D:A18, T47D:A18-TAM1, MCF-7:WS8 and MCF-7 5C cell lines.
Supplementary Figure 2 from Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Authors: Huynh Hung , Hao Huai-Xiang , Chan Stephen L. , Chen David , Ong Richard , Soo Khee Chee , Pochanard Panisa , Yang David , Ruddy David , Liu Manway , Derti Adnan , Balak Marissa N. , Palmer Michael R. , Wang Yan , Lee Benjamin H. , Sellami Dalila , Zhu Andrew X. , Schlegel Robert , Huang Alan
Published: April 2023

Mechanisms of TSC2 loss in HCC cell lines and xenografts. (A) Taqman RT-PCR analysis of TSC1 and TSC2 mRNA levels in HCC cell lines. (B) Taqman RT-PCR analysis of MZB1, TSC1 and TSC2 mRNA levels in TSC2-null Li-7 cells treated with epigenetic inhibitors. (C) Taqman RT-PCR analysis and (D) immunoblot analysis of TSC2 G305V mutant in HEK293T cells.
Supplementary Figure 4 from Significance of Polypyrimidine Tract–Binding Protein 1 Expression in Colorectal Cancer
Authors: Takahashi Hidekazu , Nishimura Junichi , Kagawa Yoshinori , Kano Yoshihiro , Takahashi Yusuke , Wu Xin , Hiraki Masayuki , Hamabe Atsushi , Konno Masamitsu , Haraguchi Naotsugu , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Masaru , Mimori Koshi , Ishii Hideshi , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Representative immunohistochemical observation of the invasive front of early stage CRC specimens. Grouping described in Table 1 was according to these findings. Scale bar: 100 ÃŽÂ¼m.
Supplementary Figure 1 from SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression
Authors: Findlay Victoria J. , Wang Cindy , Nogueira Lourdes M. , Hurst Katie , Quirk Daniel , Ethier Stephen P. , Staveley O'Carroll Kevin F. , Watson Dennis K. , Camp E. Ramsay
Published: April 2023

Supplemental Figure 1. Western blot analysis of cancer stem cell transcription factor expression in colorectal cancer cell lines. Actin was used as a loading control.
Supplementary Figure 4 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Figure 4. Effect of MLN8237 on Cleaved Caspase-3 in TNBC xenografts in vivo.
Supplementary Fig. 6 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 6. IHC analysis of tumor specimens from tumor xenografts
Supplementary Fig. 5 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 5. Bodyweight of mice during xenograft experiments
Supplemental figure legends from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Figure legends describing supplemental data.
Supplementary Fig. 1 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 1. Effect of AMG 232 on p53 activation and cell cycle arrest
Supplementary Figure Legends from Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Authors: Toren Paul J. , Kim Soojin , Pham Steven , Mangalji Azzra , Adomat Hans , Guns Emma S. Tomlinson , Zoubeidi Amina , Moore William , Gleave Martin E.
Published: April 2023

Supplementary Figure Legends.
Supplementary Figure 2 from Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Authors: Toren Paul J. , Kim Soojin , Pham Steven , Mangalji Azzra , Adomat Hans , Guns Emma S. Tomlinson , Zoubeidi Amina , Moore William , Gleave Martin E.
Published: April 2023

Supplementary Figure 2: Supplementary AR transactivation and PARP results.
Supplementary Tables 1 and 2 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary Tables 1 and 2: Primer sequences used in the study.
Supplementary Figure Legends from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary figure legends.
Supplementary Figure 3 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary Figure 3: Jagged1 knockdown had no effect on MIA PaCa-2 cells migration.
Supplementary Figure 1 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary Figure 1: Metastatic inhibtion by Jagged2 depletion in BxPC-3 using another shRNA.
Supplementary Figure 2 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 2: Alignment of all human SET domain methyltransferases
Supplemental Figure 8 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 8. Effect of ENT treatment on formation lung metastasis in NSG mice
Data Supplement from Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
Authors: Rossi Edmund A. , Rossi Diane L. , Cardillo Thomas M. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Figure S7 shows the direct action of IFN-α on Capan-1 and NCI-N87 cells. Figure S8 shows ex vivo T cell re-directed killing of BxPC3 cells with (E1)-3s.
Supplemental Figure 4 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 4. Effect of ENT on mammosphere formation
Supplementary Table 1, Figures 1 - 6 from Bicyclic Peptides Conjugated to an Albumin-Binding Tag Diffuse Efficiently into Solid Tumors
Authors: Pollaro Lisa , Raghunathan Sandeep , Morales-Sanfrutos Julia , Angelini Alessandro , Kontos Stephan , Heinis Christian
Published: April 2023

Supplementary Table (microscopy exposure times), Supplementary Figure 1 (synthesis of UK18-SA21), Supplementary Figure 2 (synthesis of UK202-SA21Alexa), Supplementary Figure 3 (micrographs of tumor sections, mice were injected with peptide), Supplementary Figure 4 (micrographs of tumor sections, mice were not injected with peptide), Supplementary Figure 5 (micrographs of tumor sections, autofluorescence), Supplementary Figure 6 (standard curve for peptide quantification).
Figure Legends for Supplemental Figures from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Figure Legends for Supplemental Figures. Figure Legends for Supplemental Figures
Supplementary Figure S1 from miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer
Authors: Tang Hailin , Liu Peng , Yang Lu , Xie Xinhua , Ye Feng , Wu Minqing , Liu Xiaoping , Chen Bo , Zhang Lijuan , Xie Xiaoming
Published: April 2023

miR-185 is downregulated in TNBC
Supplementary Figure S3 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S3: Semi-quantitative analyses of the Western blot result in Fig. 3A
Supplementary Figure S2 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S2: Over-expression of Pdcd4 enhances the anti-proliferation effects of OSI-906
Supplementary Figure S1 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S1: The expression level of Pdcd4 correlates with cell sensitivity to OSI-906
Supplementary Figures S1, S2 from Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
Authors: Hu Chaoxin , Dadon Tikva , Chenna Venugopal , Yabuuchi Shinichi , Bannerji Rajat , Booher Robert , Strack Peter , Azad Nilofer , Nelkin Barry D. , Maitra Anirban
Published: April 2023

Supplementary Figures S1, S2. Supplementary Figure 1 shows pharmacodynamic biomarkers for two of the pancreatic cancer subcutaneous patient-derived xenografts. Supplementary Figure 2 shows necropsy, indicating significantly decreased metastases in animals treated with the combination of dinaciclib + MK-2206
Supplemental Figure 5 from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich
Published: April 2023

Supplemental Figure 5: Effects of RTA 408 on morphological appearance of normal prostate epithelial cells (PrEC), normal human keratinocytes (NHEK-1) and PC3 cells (scale bars 100 μM). RTA 408 was added to cultures for 72 h at the concentrations indicated.
Data Supplement from Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
Authors: Zhang Yi-Xiang , Sicinska Ewa , Czaplinski Jeffrey T. , Remillard Stephen P. , Moss Samuel , Wang Yuchuan , Brain Christopher , Loo Alice , Snyder Eric L. , Demetri George D. , Kim Sunkyu , Kung Andrew L. , Wagner Andrew J.
Published: April 2023

LEE011 reduced RB phosphorylation in a time-dependent manner.
Supplementary Figure S2: Western blot analysis of MAPK pathway inhibition by BI 847325 in BRAF-mutant cell lines. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
Authors: Sini Patrizia , Gürtler Ulrich , Zahn Stephan K. , Baumann Christoph , Rudolph Dorothea , Baumgartinger Rosa , Strauss Eva , Haslinger Christian , Tontsch-Grunt Ulrike , Waizenegger Irene C. , Solca Flavio , Bader Gerd , Zoephel Andreas , Treu Matthias , Reiser Ulrich , Garin-Chesa Pilar , Boehmelt Guido , Kraut Norbert , Quant Jens , Adolf Günther R.
Published: April 2023

(A), MEK1 and phospho-MEK1/2; (B) ERK1/2 and phospho-ERK1/2.
Supplementary figure S1 from Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Authors: Esfandiari Arman , Hawthorne Thomas A. , Nakjang Sirintra , Lunec John
Published: April 2023

Supplementary figure S1: A) Volcano plot generated from the Wellcome Trust Sanger Institute Cosmic database showing the most significant genetic mutational determinants of response to MDM2 inhibition by Nutlin-3a. The plot shows the effect that genetic events, in commonly mutated genes in cancer, have on the IC50 for Nutlin-3a across a large panel of cell lines. The Y axis represents the p-value from multivariate ANOVA of drug gene interaction on an inverted log10 scale. This shows TP53 genetic status to be by far the strongest determinant of response to MDM2 antagonists (p=1.26e-54 ; Note this is off the Y-axis scale). The size of the circle reflects the sample size. B) Box and whiskers plot showing all the data associated with the TP53 node on the volcano plot from Supplementary figure S1A illustrating the range of sensitivities to Nutlin-3a among TP53 wild-type cell lines as determined by their IC50 values.
Supplementary Tables 1 through 3 from Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction
Authors: Jaskula-Sztul Renata , Eide Jacob , Tesfazghi Sara , Dammalapati Ajitha , Harrison April D. , Yu Xiao-Min , Scheinebeck Casi , Winston-McPherson Gabrielle , Kupcho Kevin R. , Robers Matthew B. , Hundal Amrit K. , Tang Weiping , Chen Herbert
Published: April 2023

Supplementary Table 1: List of primary antibodies and their working dilutions, Supplementary Table 2: List of secondary antibodies and their working dilutions, Supplementary Table 3: List of qRT-PCR primers
Supplementary Figure S5 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Binding of C4.4A-Ab.
Supplementary Figure S3 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Internalization of C4.4A-Ab.
Supplementary Figure 2 from Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties
Authors: Seifert Oliver , Plappert Aline , Fellermeier Sina , Siegemund Martin , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

PDF file - 126K, Supplementary Figure 2. In vitro cytotoxicity of EHD2-scTRAIL and scFv-EHD2-scTRAIL in comparison with scTRAIL
Supplementary Figure S10 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Anti-tumor efficacy of C4.4A-ADC in human nasopharyngeal carcinoma FaDu cancer xenograft mouse model.
Supplementary Movie from Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer
Authors: Takehara Kiyoto , Tazawa Hiroshi , Okada Naohiro , Hashimoto Yuuri , Kikuchi Satoru , Kuroda Shinji , Kishimoto Hiroyuki , Shirakawa Yasuhiro , Narii Nobuhiro , Mizuguchi Hiroyuki , Urata Yasuo , Kagawa Shunsuke , Fujiwara Toshiyoshi
Published: April 2023

H1299 cells stably co-transfected with KillerRed- and EGFP-expressing vectors (H1299-KillerRed-EGFP) were irradiated for 12 hours. Cells showed morphological changes following photobleaching and started to die, which could be visualized with GFP expression.
Supplementary Tables legend from Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Authors: Murone Maximilien , Vaslin Chessex Anne , Attinger Antoine , Ramachandra Raghuveer , Shetty Shankar J. , Daginakatte Girish , Sengupta Saumitra , Marappan Sivapriya , Dhodheri Samiulla , Rigotti Stefania , Bachhav Yogeshwar , Brienza Silvano , Traxler Peter , Lang Marc , Aguet Michel , Zoete Vincent , Michielin Olivier , Nicholas Courtney , Johnson Faye M. , Ramachandra Murali , McAllister Andres
Published: April 2023

Legend for Supplementary Tables:1,2,3,4
Supplemental Figure 5 from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

Validation of the GFP-based DSB repair assay panel using known DSB repair inhibitors.
Supplemental Figure 3 from Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Authors: Goglia Alexander G. , Delsite Robert , Luz Antonio N. , Shahbazian David , Salem Ahmed F. , Sundaram Ranjini K. , Chiaravalli Jeanne , Hendrikx Petrus J. , Wilshire Jennifer A. , Jasin Maria , Kluger Harriet M. , Glickman J. Fraser , Powell Simon N. , Bindra Ranjit S.
Published: April 2023

Full IC50 curves for mNHEJ, HR and cell viability for each of the 16 identified hits which inhibit DSB repair activity.
Supplementary Figures S1-S5 from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Authors: Huang Fei , Chang Han , Greer Ann , Hillerman Stephen , Reeves Karen A. , Hurlburt Warren , Cogswell John , Patel Dharmesh , Qi Zhenhao , Fairchild Craig , Ryseck Rolf-Peter , Wong Tai W. , Finckenstein Friedrich G. , Jackson Jeffrey , Carboni Joan M.
Published: April 2023

Supplementary Figures S1-S5. Supplementary Figure S1. Similarity of CNV profiles are seen from both CRC cell lines and CRC primary tumor samples with highlight on chromosome 13 copy number gain. Supplementary Figure S2: The RNA expression levels comparison between the sensitive and resistant groups in all cell lines, KRAS mutants, KRAS/BRAF-WT/WT subpopulations for IR-B, IGF1, IGF2 and IRS1. Supplementary Figure S3: Differential expression patterns of IRS2, IGF-1R, and activation of MAPK between CRC cell lines with KRAS G13D mutation and other KRAS mutations. Supplementary Figure S4: Cell lines with IRS2 CNG or sensitive to BMS-754807 had lower basal level MAPK activation. Supplementary Figure S5: IGF-1R/IR pathway signaling in LS513 and SW-403 CRC cell lines.
Supplemental Figure Legends from Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer
Authors: Meador Catherine B. , Jin Hailing , de Stanchina Elisa , Nebhan Caroline A. , Pirazzoli Valentina , Wang Lu , Lu Pengcheng , Vuong Huy , Hutchinson Katherine E. , Jia Peilin , Chen Xi , Eisenberg Rosana , Ladanyi Marc , Politi Katerina , Zhao Zhongming , Lovly Christine M. , Cross Darren A.E. , Pao William
Published: April 2023

Supplemental Figure Legends
Supplemenatl Figure1 from Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
Authors: Helfrich Barbara A. , Kim Jihye , Gao Dexiang , Chan Daniel C. , Zhang Zhiyong , Tan Aik-Choon , Bunn Paul A.
Published: April 2023

Aurora A (A) and Aurora B (B) kinase gene expression in SCLC cell lines.
Supplementary Table 1 from A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
Authors: LaBonte Melissa J. , Yang Dongyun , Zhang Wu , Wilson Peter M. , Nagarwala Yasir M. , Koch Kevin M. , Briner Colleen , Kaneko Tomomi , Rha Sun-Young , Gladkov Oleg , Urba Susan G. , Sakaeva Dina , Pishvaian Michael J. , Hsieh Ruey-Kuen , Lee Wei-Ping , Lenz Heinz-Josef
Published: April 2023

Intratumoral HER2 expression
Supplementary figure S5 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

Recombinant POSTN and TGF beta1 increase GSC272 invasion via integrin Î²1.
Supplementary figure S3 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Authors: Park Soon Young , Piao Yuji , Jeong Kang Jin , Dong Jianwen , de Groot John F.
Published: April 2023

POSTN regulates EMT and VEGF-A expression in GSCs.
Table S2 from HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
Authors: Zimel Melissa N. , Horowitz Chloe B. , Rajasekhar Vinagolu K. , Christ Alexander B. , Wei Xin , Wu Jianbo , Wojnarowicz Paulina M. , Wang Dong , Goldring Steven R. , Purdue P. Edward , Healey John H.
Published: April 2023

Composite karyotype* of cell line 4T1
Supplemental Table S1, Supplemental Material and Methods and Supplemental Figure Legends from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Supplemental Table S1. IC50 values for Nultin-3a, Carboplatin, and 1:1 Combination; Supplemental Material and Methods; Supplemental Figure Legends
Supplemental Figure S7 from Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Authors: Tonsing-Carter Eva , Bailey Barbara J. , Saadatzadeh M. Reza , Ding Jixin , Wang Haiyan , Sinn Anthony L. , Peterman Kacie M. , Spragins Tiaishia K. , Silver Jayne M. , Sprouse Alyssa A. , Georgiadis Taxiarchis M. , Gunter T. Zachary , Long Eric C. , Minto Robert E. , Marchal Christophe C. , Batuello Christopher N. , Safa Ahmad R. , Hanenberg Helmut , Territo Paul R. , Sandusky George E. , Mayo Lindsey D. , Eischen Christine M. , Shannon Harlan E. , Pollok Karen E.
Published: April 2023

Evaluation of pharmacodynamic (PD) markers in vivo.
Suppl Table 1 from FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model
Authors: Gstalder Cécile , Ader Isabelle , Cuvillier Olivier
Published: April 2023

List of antibodies used for Immunohistochemistry studies
Supplementary Table S1 from MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma
Authors: Filocamo Gessica , Brunetti Mirko , Colaceci Fabrizio , Sasso Romina , Tanori Mirella , Pasquali Emanuela , Alfonsi Romina , Mancuso Mariateresa , Saran Anna , Lahm Armin , Di Marcotullio Lucia , Steinkühler Christian , Pazzaglia Simonetta
Published: April 2023

Gene expression intensity data. Values shown represent average values for the various vehicle or treatment groups.
Supplementary Material and Methods and Figure Legends from MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma
Authors: Filocamo Gessica , Brunetti Mirko , Colaceci Fabrizio , Sasso Romina , Tanori Mirella , Pasquali Emanuela , Alfonsi Romina , Mancuso Mariateresa , Saran Anna , Lahm Armin , Di Marcotullio Lucia , Steinkühler Christian , Pazzaglia Simonetta
Published: April 2023

Supplementary Material and Methods and Figure Legends
Supplementary Table from GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Authors: Baumgart Sandra , Chen Nai-Ming , Zhang Jin-San , Billadeau Daniel D. , Gaisina Irina N. , Kozikowski Alan P. , Singh Shiv K. , Fink Daniel , Ströbel Philipp , Klindt Caroline , Zhang Lizhi , Bamlet William R. , Koenig Alexander , Hessmann Elisabeth , Gress Thomas M. , Ellenrieder Volker , Neesse Albrecht
Published: April 2023

Tissue microarray analysis of NFATc2 and Stat3
Movie S2 from ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme
Authors: Cherry Allison E. , Haas Brian R. , Naydenov Alipi V. , Fung Susan , Xu Cong , Swinney Katie , Wagenbach Michael , Freeling Jennifer , Canton David A. , Coy Jonathan , Horne Eric A. , Rickman Barry , Vicente Juan Jesus , Scott John D. , Ho Rodney J.Y. , Liggitt Denny , Wordeman Linda , Stella Nephi
Published: April 2023

The same T98G cell that is shown in Movie S1 imaged 10 min after the addition of 0.5 ÂµM ST-11. Speed = 10Ã-.
Supplementary Figure 3 from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 2157KB, Characterization of the transfected clones for msVEGFR2 and mVEGF-A production.
Supplementary Figure 4 from BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT–Driven Myeloid Leukemia
Authors: Chen Li-Tzong , Chen Chiung-Tong , Jiaang Weir-Torn , Chen Tsai-Yun , Butterfield Joseph H. , Shih Neng-Yao , Hsu John Tsu-An , Lin Hui-You , Lin Sheng-Fung , Tsai Hui-Jen
Published: April 2023

The cell cycle analysis of Kasumi-1 and KG-1 cells treated with 1uM and 50nM of BPR1J373, respectively in indicated time
Supplementary Figures S1-S12 and Supplementary Tables S1-S3 from Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression
Authors: Lee Jung-Eun , Kim Chan , Yang Hannah , Park Intae , Oh Nuri , Hua Serenus , Jeong Haneul , An Hyun Joo , Kim Sun Chang , Lee Gyun Min , Koh Gou Young , Kim Ho Min
Published: April 2023

Supplementary Figure S1. Sequence Alignment of VEGF-Grab1, VEGF-Grab3, and VEGF-Trap; Supplementary Figure S2. Analysis of N-linked Glycosylation for VEGF-Grabs and VEGF-Trap; Supplementary Figure S3. Analysis of O-linked Glycosylation in VEGF-Grab1; Supplementary Figure S4. VEGF-Grab3 displays low binding to tumor ECM; Supplementary Figure S5. Pharmacokinetic profile of VEGF-Grab1 and VEGF-Grab3; Supplementary Figure S6. Tissue accumulation of VEGF-Trap and VEGF-Grab3; Supplementary Figure S7. VEGF-Grabs or VEGF-Trap have no effects on VEGFR2 signalling, EC survival, migration, and tube formation in the absence of VEGFA; Supplementary Figure S8. Dose-dependent Inhibition of VEGFR2 Signalling with Anti-VEGF Therapy; Supplementary Figure S9. Histologic Analyses of Vital Organs after Anti-VEGF Therapy; Supplementary Figure S10. VEGF-Grab effectively suppresses the growth of established bulky macroscopic tumors; Supplementary Figure S11. Histological analyses of the kidney and liver after dose dependent anti-VEGF therapy; Supplementary Figure S12. Combination Therapy of VEGF-Grab3 and Cisplatin Enhances Intratumoral Apoptosis; Supplementary Table S1. Primer sequences for site-directed mutagenesis; Supplementary Table S2. Primer sequences for Quantitative Real Time PCR; Supplementary Table S3. Antibodies.
Supplemental data (Figures 1-6 and Table 1) from Mechanism-Based Drug Combinations with the DNA Strand–Breaking Nucleoside Analog CNDAC
Authors: Liu Xiaojun , Jiang Yingjun , Nowak Billie , Hargis Sarah , Plunkett William
Published: April 2023

Supplemental Figure 1. Structures of PARP1 inhibitors used; Supplemental Figure 2. Clonogenicity of HCT116 cells with wild type p53 and p53 KO in response to imatinib (A, 5 - 50 μM, continuous incubation) or CNDAC (B, 0.05 - 0.4 μM, 24-hour exposure); Supplemental Figure 3. HR deficient cells are sensitized to PARP inhibitors; Supplemental Figure 4. Clonogenicity of Xrcc3, Rad51D and BRCA2 hamster lines after temozolomide or CNDAC; Supplemental Figure 5. Clonogenicity of Xrcc3, Rad51D, and Brca2 CHO lines in response to bendamustine or 4-HC; Supplemental Figure 6. Clonogenicity of BRCA2, XRCC3, RAD51D, and XPF CHO lines after cisplatin or oxaliplatin; Supplemental Table 1. IC50 values of clonogenic assays in RAD51D and BRCA2 hamster lines in response to paclitaxel or docetaxel.
Supplemental figure 2 from Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models
Authors: Jansen Marc H.A. , Lagerweij Tonny , Sewing A. Charlotte P. , Vugts Danielle J. , van Vuurden Dannis G. , Molthoff Carla F.M. , Caretti Viola , Veringa Susanna J.E. , Petersen Naomi , Carcaboso Angel M. , Noske David P. , Vandertop W. Peter , Wesseling Pieter , van Dongen Guus A.M.S. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Supplemental Figure 2: VEGF mRNA expression in DIPG in comparison to normal brain (n=31) as analyzed by R2 (R2.amc.nl), clustered by stage of disease; unknown (n=10), pretreatment (n=2) and postmortem (n=23)
Supplemenatry Fig. S1 from The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma
Authors: Olsson P. Olof , Gustafsson Renata , in 't Zandt René , Friman Tomas , Maccarana Marco , Tykesson Emil , Oldberg Åke , Rubin Kristofer , Kalamajski Sebastian
Published: April 2023

Collagen synthesis in STI571-treated KAT-4 carcinoma
Supplementary Materials and Methods and Supplementary Tables S1-S5 from αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4
Authors: Jin Zhao-Hui , Furukawa Takako , Degardin Mélissa , Sugyo Aya , Tsuji Atsushi B. , Yamasaki Tomoteru , Kawamura Kazunori , Fujibayashi Yasuhisa , Zhang Ming-Rong , Boturyn Didier , Dumy Pascal , Saga Tsuneo
Published: April 2023

Supplementary Files contain (1) Supplementary Materials and Methods for ï�¡Vï�¢3 expression analysis, autoradiography and histological analysis, and hematology and hepatorenal function; (2) Supplementary Tables S1-S5; and (3) Supplementary Figures S1-S5. Table S1ï€­Effects of 37 MBq (1 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys on hepatorenal functions of U87MG tumor-bearing mice; Table S2ï€­Blood cell counts of U87MG tumor-bearing mice at various time points post-injection of 37 MBq (1 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys; Table S3ï€­Blood cell counts of U87MG tumor-bearing mice at various time points after single dose administrations of 37 and 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Table S4ï€­Effects of 74 MBq (2 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 + GF/Lys on hepatorenal functions of normal mice; Table S5ï€­Human absorbed doses extrapolated from the biodistribution data of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in U87MG tumor-bearing mice
Figure S1 from Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors
Authors: Sengupta Satarupa , Sobo Matthew , Lee Kyungwoo , Senthil Kumar Shiva , White Angela R. , Mender Ilgen , Fuller Christine , Chow Lionel M.L. , Fouladi Maryam , Shay Jerry W. , Drissi Rachid
Published: April 2023

Telomerase activity in pediatric brain tumor cells MB004, R0315-GBM, SU-DIPG-VI, CCHMC-DIPG-1, D-458, D-425, in normal diploid fibroblast cells HFF and HFF+hTERT, and in osteosarcoma cells Saos2 and U2OS. (-) C, (+) C, and IC indicate negative control, positive control, and internal control respectively. Telomerase products are indicated.
Figure S2 from Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
Authors: Bollard Julien , Patte Céline , Massoma Patrick , Goddard Isabelle , Gadot Nicolas , Benslama Noura , Hervieu Valérie , Ferraro-Peyret Carole , Cordier-Bussat Martine , Scoazec Jean-Yves , Roche Colette , Walter Thomas , Vercherat Cécile
Published: April 2023

Figure S2 shows the bliss analyses for combinations of streptozotocin with everolimus, MK-2206, BKM120 or BEZ235 in INS-1E cells.
Supplementary Figure S7. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Authors: Patel Hetal , Periyasamy Manikandan , Sava Georgina P. , Bondke Alexander , Slafer Brian W. , Kroll Sebastian H. B. , Barbazanges Marion , Starkey Richard , Ottaviani Silvia , Harrod Alison , Aboagye Eric O. , Buluwela Laki , Fuchter Matthew J. , Barrett Anthony G. M. , Coombes R. Charles , Ali Simak
Published: April 2023

Combinatorial inhibition of breast cancer cells with a combination of ICEC0942 and anti-estrogens.
Figure S1 from Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer
Authors: Buechel Megan , Dey Anindya , Dwivedi Shailendra Kumar Dhar , Crim Aleia , Ding Kai , Zhang Roy , Mukherjee Priyabrata , Moore Kathleen N. , Cao Liangxian , Branstrom Arthur , Weetall Marla , Baird John , Bhattacharya Resham
Published: April 2023

PTC-028 inhibits endometrial cancer cell viability
Supplementary figures 1-6 and Supplementary Table 1 from Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors
Authors: Loganathan Sudan N. , Tang Nan , Holler Albert E. , Wang Nenghui , Wang Jialiang
Published: April 2023

Figure S1. Expression of Myr-AKT1 in TC32 and TC71 cells. Figure S2. The blockade of IGF1R sensitizes Ewing sarcoma cells to BET inhibitors. Figure S3. Dose-dependent response to the combination of BET inhibitors and IGF1R inhibitors in Ewing sarcoma cells. Figure S4. Dose-dependent response to the combination of BET inhibitors and MEK inhibitors in Ewing sarcoma cells. Figure S5. IGF1R inhibition does not change expression of EWS-FLI1 or its target genes. Supplementary S6.(A) TC32 xenograft tumor growth after discontinuation of drug administration in the arm treated with NHWD870 and BMS754807. (B) Representative image of Ki67 and (C) cleaved caspase 3 staining in TC32 and COG-352 xenograft tumors following 3-day treatment. The bars represent 100 μm in the images. Supplementary Table S1. Sequences of qRT-PCR primers.
Supplementary Figure S3 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
Authors: Howes Jennifer E. , Akan Denis T. , Burns Michael C. , Rossanese Olivia W. , Waterson Alex G. , Fesik Stephen W.
Published: April 2023

Treatment with 17-AAG does not cause modulation of RAS-GTP levels. HeLa cells were treated with 1 μM 17-AAG over a time course of up to 180 minutes. EGF (50 ng/mL for 5 minutes) was used as a positive control. Two biological repeats of this experiment were independently conducted.
Figure S3 from Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts
Authors: Noto Fallon K. , Adjan-Steffey Valeriya , Tong Min , Ravichandran Kameswaran , Zhang Wei , Arey Angela , McClain Christopher B. , Ostertag Eric , Mazhar Sahar , Sangodkar Jaya , DiFeo Analisa , Crawford Jack , Narla Goutham , Jamling Tseten Y.
Published: April 2023

Immunophenotyping of the SDR rat. Analysis of SDR whole blood demonstrates greatly diminished T and B cells compared to the wild-type rat. A, The wild-type rat has a significant population of circulating CD4+, CD8+, and CD4/CD8 double positive T cell populations compared to the SDR rat. B, The wild-type rat has over 20% B220/IgM double positive mature B cells, compared to 3.5% in the SDR rat. C, The SDR rat has slightly less circulating NK cells, unlike what is observed in the spleen. Panels are representative of 3 wild-type and 3 SDR rats. Left panels: wild-type rat. Right panels: SDR rat.